Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Annals of Hematology|January 14, 2018
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myelomaGuillemette Fouquet, Lionel Karlin, Margaret Macro, et al.
Blood|August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaPhilippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.
Haematologica|September 29, 2022
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myelomaAnais Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Blood|January 9, 2007
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeHervé Avet-Loiseau, Michel Attal, Philippe Moreau, et al.
Blood|January 11, 2015
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsXavier Leleu, Lionel Karlin, Margaret Macro, et al.
The New England Journal of Medicine|September 4, 2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myelomaLotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
The New England Journal of Medicine|June 6, 2022
Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Alfred L Garfall, Niels W C J van de Donk, et al.
Blood|November 19, 2017
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myelomaThierry Facon, Meletios A Dimopoulos, Angela Dispenzieri, et al.
Pageof 7